Literature DB >> 18759044

Identification of tumor metastasisrelated gene TMSG-1 by mRNA differential display.

Chunshu Ma1, Yuxin Liu, Jie Zheng, Weigang Fang, Jiangfeng You, Jieliang Wang, Xianglin Cui, Bingquan Wu.   

Abstract

To investigate genes involved in cancer metastasis, mRNA differential display was used to compare the levels of gene expression of two cancer sublines derived from prostate carcinoma cell PC-3M that had different metastatic potentials. The differentially expressed genes were confirmed by Northern blot, and sequenced. The fulllength cDNA of a tumor metastasis suppressor gene (TMSG-1) was obtained by using EST assembling and verified by RT-PCR and sequencing. The results showed that expression levels of TMSG-1 were lower in the highly metastatic cell line 1E8, compared with the nonmetastatic cell line 2B4. The difference was significant. Fulllength cDNA of TMSG-1 was about 2 kb, containing an open reading frame that encoded a protein of 230 amino acids. GenBank Blastn showed no marked homology with known genes. The functional prediction of amino acids sequence encoded by TMSG-1 gene indicated TMSG-1 protein was transmembrane protein, with 3 transmembrane domains, 3 putative protein kinase phosphorylation sites, 2 casein kinase II phosphorylation sites and 1 Nmyristoylation site. The pattern of TMSG1 expression in 6 types of human tumor tissues indicated levels of transcripts were the highest in prostate carcinoma. TMSG-1 had lower expression in metastases of lung carcinoma compared to primary lung carcinoma. Similarly the expression levels were higher in welldifferentiated colon carcinoma than that in poorly differentiated colon carcinoma. TMSG-1 could also be detected in breast, ovarian, and pancreatic carcinoma. In 9 samples of primary gastric carcinoma tissues, RT-PCR and densitometric analysis demonstrated TMSG-1 expression levels in samples with lymph node metastases had a decreased tendency, compared to those without lymph node metastases. The difference was significant by student's t test (P< 0.05). These results indicated TMSG-1 expression levels were inversely correlated with tumor metastatic potential.

Entities:  

Year:  2002        PMID: 18759044     DOI: 10.1360/02yc9061

Source DB:  PubMed          Journal:  Sci China C Life Sci        ISSN: 1006-9305


  6 in total

1.  Silencing of TMSG1 enhances metastasis capacity by targeting V-ATPase in breast cancer.

Authors:  Yuan Zi; Wenjian Zhao; Jun Zhou; Hanjiang He; Ming Xie
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

2.  LASS2/TMSG1 inhibits growth and invasion of breast cancer cell in vitro through regulation of vacuolar ATPase activity.

Authors:  Fang Mei; Jiangfeng You; Beiying Liu; Mengxue Zhang; Jiangying Liu; Bo Zhang; Fei Pei
Journal:  Tumour Biol       Date:  2014-12-12

3.  Evaluation of CERS2 Gene as a Potential Biomarker for Bladder Cancer.

Authors:  Ahmed Faris Aldoghachi; Aminuddin Baharudin; Umar Ahmad; Soon Choy Chan; Teng Aik Ong; Rosna Yunus; Azad Hassan Razack; Khatijah Yusoff; Abhi Veerakumarasivam
Journal:  Dis Markers       Date:  2019-09-15       Impact factor: 3.434

4.  Alternative splicing of ceramide synthase 2 alters levels of specific ceramides and modulates cancer cell proliferation and migration in Luminal B breast cancer subtype.

Authors:  Trishna Pani; Kajal Rajput; Animesh Kar; Harsh Sharma; Rituparna Basak; Nihal Medatwal; Sandhini Saha; Gagan Dev; Sharwan Kumar; Siddhi Gupta; Arnab Mukhopadhyay; Dipankar Malakar; Tushar Kanti Maiti; Aneeshkumar G Arimbasseri; S V S Deo; Ravi Datta Sharma; Avinash Bajaj; Ujjaini Dasgupta
Journal:  Cell Death Dis       Date:  2021-02-10       Impact factor: 8.469

5.  The role of LASS2 in regulating bladder cancer cell tumorigenicity in a nude mouse model.

Authors:  Yujin Chen; Haifeng Wang; Tao Xiong; Renchao Zou; Zhaoran Tang; Jiansong Wang
Journal:  Oncol Lett       Date:  2017-09-04       Impact factor: 2.967

6.  Overexpression of LASS2 inhibits proliferation and causes G0/G1 cell cycle arrest in papillary thyroid cancer.

Authors:  Feng Zeng; Liangliang Huang; Xiaoming Cheng; Xiaoli Yang; Taolang Li; Guoli Feng; Yingqi Tang; Yan Yang
Journal:  Cancer Cell Int       Date:  2018-10-01       Impact factor: 5.722

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.